Evofem Biosciences (EVFM) Proxy Filing summary

Executive summary

• The proxy filing details a proposed merger between Evofem Biosciences, Inc. and Aditxt, Inc., with Evofem becoming a wholly owned subsidiary of Aditxt upon closing, expected in late 2024.

• The merger consideration includes $1.8 million in cash for common shareholders and a one-to-one exchange of Series E-1 Preferred Stock for Aditxt Series A-2 Preferred Stock.

• The transaction is subject to multiple closing conditions, including shareholder approvals, regulatory consents, conversion of preferred stock, and completion of equity investments by Aditxt.

• The merger agreement has been amended to adjust equity investment dates and extend the outside closing date to November 29, 2024.

• Both companies face ongoing financial and operational risks, including compliance with Nasdaq and OTC listing requirements, and the need for additional capital.

Voting matters and shareholder proposals

• Shareholders are asked to approve the merger agreement and an adjournment proposal to allow for further proxy solicitation if needed.

• Approval of the merger requires a majority of the combined voting power of common and Series E-1 shares; adjournment requires a majority of votes cast.

• Dissenting shareholders have appraisal rights under Delaware law if they follow specific procedures.

Board of directors and corporate governance

• Post-merger, the surviving company’s officers will be Saundra Pelletier and Ivy Zhang; directors will be Saundra Pelletier, Amro Albanna, and Lisa Rarick.

• The board recommends voting in favor of both proposals and has the right to abandon the merger if deemed not in shareholders’ best interests.

• Evofem’s board is currently composed of experienced professionals in women’s health, finance, and regulatory affairs.